Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 8/20 | 0.50 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.43 |
| ▸ | AKT1 | P31749 | 2/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21598459 | 0.90 | MEN1 (0.46) | NOTUMUCHL1ALDH1A1HPGDAKR1C3 | |
| SCHEMBL4532424 | 0.84 | NOTUM (0.71) | NOTUMUCHL1 | |
| SCHEMBL29229926 | 0.81 | LMNA (0.43) | NOTUMALDH1A1HPGDTSHRLMNA | |
| SCHEMBL30659423 | 0.81 | NOTUM (0.73) | NOTUMPIK3CDCYP3A4PIK3CAPIK3CB | |
| SCHEMBL2375244 | 0.81 | NOTUM (0.73) | NOTUMPIK3CDCYP3A4PIK3CAPIK3CB | |
| SCHEMBL23042904 | 0.81 | NOTUM (0.73) | NOTUMPIK3CDCYP3A4PIK3CAPIK3CB | |
| SCHEMBL19436139 | 0.80 | NOTUM (0.49) | NOTUMUCHL1PIK3CDCYP3A4PIK3CA | |
| SCHEMBL31253137 | 0.78 | NOTUM (0.43) | NOTUMUCHL1ALDH1A1HPGDHTR2C | |
| SCHEMBL23042881 | 0.78 | NOTUM (0.42) | NOTUMALDH1A1HPGDAKT1HTR2C | |
| SCHEMBL17498190 | 0.78 | AKT1 (0.47) | NOTUMALDH1A1HPGDAKT1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024133499-A1 | GLYCINE DERIVATIVES WITH P2X4 RECEPTOR-BLOCKING ACTIVITY AS DIAGNOSTICS AND FOR THE TREATMENT OF PAIN, INFLAMMATION, CANCER, AND OTHER P2X4 RECEPTOR-RELATED DISEASES | RHEINISCHE-FRIEDRICH-WILHELMS-UNIVERSITÄT BONN (DE) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024085699-A1 | COMPOUND FOR SHP2 PROTEIN DEGRADATION AND MEDICAL USES THEREOF | 주식회사 유빅스테라퓨틱스 | 2024-04-25 | — | — | WO | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2021149767-A1 | HETEROCYCLIC DERIVATIVE | 大日本住友製薬株式会社 | 2021-07-29 | — | — | WO | disclosed |
| WO-2021141041-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | 大日本住友製薬株式会社 | 2021-07-15 | — | — | WO | disclosed |
| WO-2021039961-A1 | RING-FUSED PYRAZOLE DERIVATIVE | 大日本住友製薬株式会社 | 2021-03-04 | — | — | WO | disclosed |
| WO-2020017587-A1 | PYRIDAZINONE DERIVATIVE | 大日本住友製薬株式会社 | 2020-01-23 | — | — | WO | disclosed |
| WO-2016025933-A2 | SUBSTITUTED POLYCYCLIC ANTIBACTERIAL COMPOUNDS | PTC THERAPEUTICS, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| EP-2557923-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | Curis, Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| EP-2385832-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | Curis, Inc. (US) | 2011-11-16 | — | — | EP | disclosed |
| WO-2011130628-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | CURIS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| US-8040979-B2 | Generating a phase value for a complex signal | INFINEON TECHNOLOGIES AG (DE) | 2011-10-18 | — | — | US | disclosed |
| WO-2010080996-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. (US) | 2010-07-15 | — | — | WO | disclosed |